Binding Mode
ChemicalBook > CAS DataBase List > XL518

XL518

Binding Mode
Product Name
XL518
CAS No.
934660-93-2
Chemical Name
XL518
Synonyms
CobiMetinib;GDC-0973;XL518;RG7420;CS-1977;Cobimetinib-D4;GDC-0973/RG7420;XL518 ,GDC-0973;XL518 USP/EP/BP;GDC-0973(XL-518)
CBNumber
CB32551361
Molecular Formula
C21H21F3IN3O2
Formula Weight
531.31
MOL File
934660-93-2.mol
More
Less

XL518 Property

Melting point:
165 - 166°C
Boiling point:
565.9±50.0 °C(Predicted)
Density 
1.706
storage temp. 
Refrigerator
solubility 
Chloroform (Slightly), DMSO (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
form 
Solid
pka
13.13±0.20(Predicted)
color 
Off-White
More
Less

Safety

HS Code 
29333990
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
19563
Product name
Cobimetinib
Purity
≥98%
Packaging
1mg
Price
$49
Updated
2024/03/01
Cayman Chemical
Product number
19563
Product name
Cobimetinib
Purity
≥98%
Packaging
5mg
Price
$179
Updated
2024/03/01
Cayman Chemical
Product number
19563
Product name
Cobimetinib
Purity
≥98%
Packaging
10mg
Price
$333
Updated
2024/03/01
Cayman Chemical
Product number
19563
Product name
Cobimetinib
Purity
≥98%
Packaging
25mg
Price
$711
Updated
2024/03/01
TRC
Product number
X746250
Product name
XL518
Packaging
10mg
Price
$275
Updated
2021/12/16
More
Less

XL518 Chemical Properties,Usage,Production

Binding Mode

Cobimetinib binds to a specific allosteric pocket adjacent to the ATP site of MEK1, forming a highly complex network of interactions involving the terminal aminoethanol moiety with both the catalytic loop Asp190 and the ATP γ-phosphate (Figs. 2 and 3). The amide oxygen hydrogen bonds to the primary amine of Lys97. The piperidine nitrogen approaches the catalytic loop, thereby enabling interactions with both γ-phosphoryl oxygen of ATP and the carboxylic acid residue of Asp190. The azetidine hydroxyl also engages in interactions with Asp190 and the γ-phosphoryl oxygen of ATP.

Description

Cobimetinib, codeveloped by Genentech and Exelixis, was approved in August 2015 in Switzerland and November 2015 in the U.S. and Europe for the treatment of unresectable or metastatic BRAFV600 mutationpositive melanoma when used in combination with vemurafenib. Cobimetinib is a potent, highly selective reversible inhibitor of mitogen-activated protein kinases (MEK) 1 and 2,120 which serves to inhibit phosphorylation of ERK1/2,121 disrupting the MAPK pathway which is responsible for cell proliferation, cell survival, and migration.122 Combination of cobimetinib with vemurafenib, an important BRAF inhibitor,123 enables targeting of multiple points on the MAPK pathway, leading to overall enhanced tumor cell apoptosis and response as compared to stand-alone treatment with vemurafenib.124 Specifically, in a representative trial of previously untreated patients with BRAFV600 mutation-positive, unresectable, stage IIIc or IV melanoma, combination of these two therapies led to a significantly improved progression-free survival and overall response rate versus patients treated only with vemurafenib.

Uses

A potent, selective, orally bioavailable inhibitor of MEK1, a component of the RAS/RAF/MEK/ERK pathway. It inhibits proliferation and stimulates apoptosis in a variety of human tumor cell lines. In preclinical xenograft models, oral administration of XL518 results in sustained inhibition of pERK in tumor tissue, but not brain tissue, leading to tumor growth inhibition and regression at well tolerated doses.

Definition

ChEBI: Cobimetinib is a member of the class of N-acylazetidines obtained by selective formal condensation of the carboxy group of 3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid with the secondary amino group from the azetidine ring of 3-[(2S)-piperidin-2-yl]azetidin-3-ol. An inhibitor of mitogen-activated protein kinase that is used (as its fumarate salt) in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma. It has a role as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor and an antineoplastic agent. It is a member of piperidines, a N-acylazetidine, a tertiary alcohol, an aromatic amine, a secondary amino compound, a difluorobenzene and an organoiodine compound. It is a conjugate base of a cobimetinib(1+).

brand name

Cotellic

General Description

Class: dual threonine/tyrosine kinase; Treatment: melanoma with BRAF mutations; Other name: GDC-0973, XL518; Oral bioavailability = 46%; Elimination half-life = 44 h; Protein binding = 95%

Pharmacokinetics

Cobimetinib has only moderate oral bioavailability (46%), likely due to metabolism rather than incomplete absorption. However, it displays prolonged elimination half-life (44 h), which supports a once-daily dosing regimen (60 mg). Following oral administration, the unchanged cobimetinib and metabolite 4 were the major circulating components in the plasma up to 48 hours post dose (AUC0–48), accounting for 21% and 18% of all the circulating drug-related components, respectively (Fig. 4).

Clinical Use

Protein kinase inhibitor:
Treatment of unresectable or metastatic melanoma with a BRAF V600 mutation in combination with vemurafenib

Synthesis

Structurally, cobimetinib features an interesting azetidinol substructure appended to the 2-position of a piperidine, rendering the 2-carbon of the piperidine as a stereogenic center bearing the (S)-configuration. While the early discovery routes to cobimetinib relied on a piperidine resolution-based route for accessing the cobimetinib core, the scale route to this drug employs an impressive N-cyanomethyl oxazolidine chiral auxiliary-mediated sequence to induce strereocontrol, generating the requisite stereocenter with excellent selectivity and requiring no chromatographic purification in the overall synthetic sequence. Toward this end, the most likely scale synthetic approach was initiated with deprotonation of commercially available (3S,5R,8aS)-3-phenyl-hexahydrooxazolo[ 3,2-a]pyridine-carbonitrile (180), followed by addition of commercial 3-oxo-azetidine-1-carboxylic acid tert-butyl ester (181), yielded 182 in high purity (92%) after distillation and providing a rapid route to the core structure of cobimetinib. One-pot ring opening and reduction of 182 was accomplished by exposing this hemiaminal to acetic acid and sodium cyanoborohydride, giving rise to intermediate 183. This carbamate could be further reacted with aqueous HCl in toluene to liberate the azetidine amine salt in high purity (97.6%), which underwent immediate acylation with commercially available 2,3,4-trifluoro-benzoyl chloride (184) to enable formation of intermediate 185 in 85% purity after aqueous workup. Reductive cleavage of the chiral auxiliary of 185 with Pd/C and H2 under aqueous acidic conditions (AcOH, aq HCl) yielded the desired piperidine amine, which could be isolated as a solid (99.6% pure) after trituration with aqueous HCl. Finally, aromatic fluoride substitution with commercially available aniline 186 under basic conditions provided cobimetinib in 99.7% purity after slow precipitation from toluene (it is important to note that the authors offer no comment as to the regioselectivity of this aromatic substitution reaction). While the drug reportedly exists as a fumarate salt, no synthetic reports describing the conversion of cobimetinib to the corresponding fumarate salt were available in the chemical literature to our knowledge at the time of publication.

target

Primary target: MEK1/2

Drug interactions

Potentially hazardous interactions with other drugs
Antifungals: concentration increased by itraconazole.
Antipsychotics: increased risk of agranulocytosis - avoid.

Metabolism

Metabolised by oxidation by CYP3A and glucuronidation by UGT2B7. Extensively metabolised and eliminated in faeces

XL518 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

XL518 Suppliers

Chembest Research Laboratories Limited
Tel
+86-21-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6005
Advantage
61
Shanghai VastPro Technology Development Co., Ltd.
Tel
021-20608178 18930468532
Email
sales@vastprotech.com
Country
China
ProdList
15
Advantage
58
Shanghai Boyle Chemical Co., Ltd.
Tel
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2922
Advantage
55
Beijing HwrkChemical Technology Co., Ltd
Tel
010-89508211 18501085097
Fax
010-89508210
Email
sales.bj@hwrkchemical.com
Country
China
ProdList
8418
Advantage
55
Jia Xing Isenchem Co.,Ltd
Tel
0573-85285100 18627885956
Fax
0573-85285100
Email
isenchem@163.com
Country
China
ProdList
9413
Advantage
66
Chemsky (shanghai) International Co.,Ltd
Tel
021-50135380
Email
shchemsky@sina.com
Country
China
ProdList
15402
Advantage
60
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
meilunui@163.com
Country
China
ProdList
4727
Advantage
58
Shanghai Topbiochem Technology Co., Ltd
Tel
021-58170097
Email
info@topbiochem.com
Country
China
ProdList
9459
Advantage
58
NCE Biomedical Co.,Ltd.
Tel
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Fax
+86-27-87599188
Country
China
ProdList
1493
Advantage
55
Shanghai T&W Pharmaceutical Co., Ltd.
Tel
+86 21 61551611
Fax
+86 21 50676805
Country
China
ProdList
9891
Advantage
58
Shanghai Jian Chao Chemical Technology Co., Ltd.
Tel
18017383231 18017383231
Fax
qq:2817624287
Email
lyh_antaeus@163.com
Country
China
ProdList
9347
Advantage
55
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Fax
(86) 21-58955996
Email
info@chemexpress.com
Country
China
ProdList
7552
Advantage
61
UHN Shanghai Research & Development Co., Ltd.
Tel
021-58958002 18930822973
Fax
+86 (21) 5895-8628
Email
SALES@UHNSHANGHAI.COM
Country
China
ProdList
977
Advantage
58
Shanghai Aladdin Bio-Chem Technology Co.,LTD
Tel
400-400-6206333 18521732826
Fax
021-50323701
Email
market@aladdin-e.com
Country
China
ProdList
25003
Advantage
65
Bsisun HK Imoprt And Export Company Limited
Tel
+86-18068513926
Fax
0086-519-85153711
Country
China
ProdList
1277
Advantage
55
TargetMol Chemicals Inc.
Tel
021-021-33632979 15002134094
Fax
021-33632979
Email
marketing@targetmol.com
Country
China
ProdList
7783
Advantage
58
SHANGHAI SINOCHEMTECH CO.,LTD.
Tel
86-21-37788339
Fax
86-21-5768-0031
Country
China
ProdList
76
Advantage
55
CEG Chemical Science&Technology Co., Ltd.
Tel
Mobile:13665161512
Fax
+86-510-68873513
Country
China
ProdList
1785
Advantage
58
GIHI CHEMICALS CO.,LTD
Tel
0086-571-86217390
Fax
0086-571-86217391
Email
Sales@gihichem.com
Country
China
ProdList
860
Advantage
58
ShangHai Caerulum Pharma Discovery Co., Ltd.
Tel
18149758185 18149758185
Email
sales-cpd@caerulumpharma.com
Country
China
ProdList
3466
Advantage
58
DKMbiochem.Co. Ltd
Tel
15901859516
Fax
15901859516
Email
sales@DKMbiochem.com
Country
China
ProdList
344
Advantage
58
ChemStrong Scientific Co.,Ltd
Tel
0755-0755-66853366 13670046396
Fax
0755-28363542
Email
sales@chem-strong.com
Country
China
ProdList
18042
Advantage
56
Shanghai CanSpecsci Instrument Co., Ltd.
Tel
400-6087598 15021221957
Fax
4006087598-8012
Email
order@canspecsci.com
Country
China
ProdList
2045
Advantage
56
Suzhou yacoo science co.,Ltd
Tel
0512-87182056 18013166090
Fax
0512-87182056
Email
lingling.qi@yacoo.com.cn
Country
China
ProdList
7295
Advantage
60
Shanghai Synteam Biochem CO.,ltd
Tel
+86-021-58380978 +86-18017016373
Fax
021-58380978
Email
info@systeambc.com
Country
China
ProdList
941
Advantage
50
AdooQ Bioscience CHINA
Tel
025-58849295 18951903616;
Fax
025-68650336
Email
info@adooq.cn
Country
China
ProdList
2990
Advantage
60
LETOPHARM LIMITED
Tel
+86-21-5821 5861
Fax
+86-21-5106 2861
Email
sales@letopharm.com
Country
China
ProdList
2384
Advantage
58
Shanghai Lollane Biological Technology Co.,Ltd.
Tel
021-52996696,15000506266 15000506266
Fax
+86-21-52996696
Country
China
ProdList
4512
Advantage
55
Intelligence Pharm Science(Shanghai) Co., Ltd.
Tel
021-57898186
Fax
021-37699262
Country
China
ProdList
449
Advantage
55
Shanghaizehan biopharma technology co., Ltd.
Tel
021-61350663 13052117465
Fax
021-61350662
Email
sales@zehanbiopharma.com
Country
China
ProdList
1009
Advantage
55
Shanghai Synchem Pharma Co., ltd
Tel
21-619849051-1 18521059765
Email
synchempharma@aliyun.com
Country
China
ProdList
6463
Advantage
55
Yangzhou QinYuan Pharmaceutical Co., Ltd.
Tel
0514-80939770 13773367191
Fax
0514-82664689
Email
yzqyyykj@163.com
Country
China
ProdList
240
Advantage
55
Shanghai Rochi Pharmaceutical Co., Ltd.
Tel
021-38751876 15000076078
Fax
021-50275764
Email
Info@rochipharma.com
Country
China
ProdList
568
Advantage
55
Codow Chemical Co.,Ltd.
Tel
18620099427
Fax
+86-20-62619665
Email
amy@howeipharm.com
Country
China
ProdList
17687
Advantage
55
Pharmacodia (Beijing) Co.,Ltd
Tel
+86-400-851-9921
Fax
+86-10-82826195
Email
sales@pharmacodia.com
Country
China
ProdList
2317
Advantage
55
ShangHai Siyan Biological Technology Co., Ltd.
Tel
021-50908862,442785678,326799392 18721037013
Fax
021-50908862
Email
siyansales@126.com
Country
China
ProdList
9627
Advantage
58
Guangzhou QiYun Biotechnology Co., Ltd.
Tel
020-61288194 61288195
Fax
020-61288700
Email
505721671@qq.com
Country
China
ProdList
3866
Advantage
58
Shanghai QianYan Bio-technology Co., Ltd
Tel
02781293128
Email
orders@biochemsafebuy.com
Country
China
ProdList
9923
Advantage
55
Lancrix Chemicals
Tel
86-21-50817262
Fax
86-21-57712035
Email
sales@lancrix.com
Country
China
ProdList
1502
Advantage
55
Cangzhou Enke Pharma-tech Co., Ltd.
Tel
0317-5296180 15533709196
Fax
0317-5106596
Email
sale@enkepharma.com
Country
China
ProdList
1898
Advantage
55
Chengdu Dianchun Technology Co., Ltd
Tel
400-1166-196 18502815961
Fax
QQ:800101999
Email
cdhxsj@163.com
Country
China
ProdList
14603
Advantage
60
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Fax
QQ:2853530913
Email
2853530910@QQ.com
Country
China
ProdList
8011
Advantage
62
Shanghai Rechem science Co., Ltd.
Tel
21-31433387 15618786686
Fax
QQ:1369748377
Email
sales@rechemscience.com
Country
China
ProdList
2988
Advantage
58
Beijing Solarbio Science & Tecnology Co., Ltd.
Tel
010-50973130 4009686088
Email
3193328036@qq.com
Country
China
ProdList
29785
Advantage
68
Amadis Chemical Company Limited
Tel
571-89925085
Fax
0086-571-89925065
Email
sales@amadischem.com
Country
China
ProdList
131957
Advantage
58
Beijing Jin Ming Biotechnology Co., Ltd.
Tel
010-60605840 18892239720
Fax
010-60605840
Email
psaitong@jm-bio.com
Country
China
ProdList
12306
Advantage
58
Zhongshan Geometric Biological Technology Co., Ltd.
Tel
+86-13168912896
Country
China
ProdList
253
Advantage
58
Medi-tech Bioscientific Co., Ltd.
Tel
0519-83246372 13585352506
Fax
0519-83246372
Country
China
ProdList
1844
Advantage
58
Chuzhou KeMail Chemical Technology Co., Ltd
Tel
0550-5196001 15000891977
Fax
0550-5196001
Email
wj520wjxby@126.com
Country
China
ProdList
1847
Advantage
55
Lynnchem
Tel
86-(0)29-85992781 17792393971
Email
info@lynnchem.com
Country
China
ProdList
4587
Advantage
58
More
Less

View Lastest Price from XL518 manufacturers

Zhuozhou Wenxi import and Export Co., Ltd
Product
Cobimetinib 934660-93-2
Price
US $15.00-10.00/KG
Min. Order
1KG
Purity
99%+ HPLC
Supply Ability
Monthly supply of 1 ton
Release date
2021-07-10
Zhuozhou Wenxi import and Export Co., Ltd
Product
Cobimetinib 934660-93-2
Price
US $15.00-10.00/KG
Min. Order
1KG
Purity
99%+ HPLC
Supply Ability
Monthly supply of 1 ton
Release date
2021-07-09
Shanghai VastPro Technology Development Co., Ltd.
Product
Cobimetinib 934660-93-2
Price
US $0.00/KG
Min. Order
1g
Purity
99
Supply Ability
100kg
Release date
2020-08-11

934660-93-2, XL518Related Search:


  • XL518
  • GDC-0973
  • RG7420
  • [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)aMino]phenyl][3-hydroxy-3-[(2S)-2-piperidinyl]-1-azetidinyl]Methanone
  • GDC-0973(XL-518)
  • (S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylaMino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)Methanone
  • XL518 ,GDC-0973
  • CobiMetinib
  • GDC-0973/RG7420
  • Methanone, [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)aMino]phenyl][3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl]-
  • Cobimetinib,GDC-0973
  • Cobimetinib (GDC-0973, RG7420)
  • Cobimetinib (GDC-0973,XL 518)
  • Cobimetinib(XL518)
  • GDC0973, XL518, Cobimetinib
  • Cobimetinib, >=98%
  • [3,4-Bis(Fluoranyl)-2-[(2-Fluoranyl-4-Iodanyl-Phenyl)amino]phenyl]-[3-Oxidanyl-3-[(2s)-Piperidin-2-Yl]azetidin-1-Yl]methanone
  • XL518, Co bimetinib
  • CS-1977
  • [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone
  • 1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-[(2S)-2-piperidinyl]-3-azetidinol
  • XL-518;GDC 0973 (XL518);COBIMETINIB;GDC0973;XL-518;XL 518;GDC 0973
  • GDC-0973 (Cobimetinib)
  • XL518 USP/EP/BP
  • Cobimetinib (GDC-0973, RG-7420, XL-518)
  • Cobimetinib-D4
  • (S)-[3,4-Difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-(2-piperidyl)-1-azetidinyl]methanone
  • 934660-93-2
  • 93466-93-2
  • C21H21F3IN3O2
  • MAPK
  • API
  • Aromatics
  • Heterocycles
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Protein Kinase Inhibitors and Activators